| Status | Suspended |
| Process | STA pre-2018 |
| Referral date | 01 September 2010 |
| Topic area |
|
| Description |
Scoped within Batch 13 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | 18 January 2012 |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
Project Team
| Communications manager: | Alice Law |
| Executive Lead: | Peter Littlejohns |
| Project manager: | Rebecca Pye |
| Technical Lead: | Pall Jonsson |
Consultees
| Manufacturers/sponsors | Allos Therapeutic (pralatrexate) |
| Others | Department of Health |
| NHS Camden | |
| NHS Middlesbrough | |
| Welsh Assembly Government | |
| Patient/carer groups | Afiya Trust |
| African Caribbean Leukaemia Trust (ACLT) | |
| Anthony Nolan Bone Marrow Trust | |
| Black Health Agency | |
| CANCERactive | |
| Cancer Black Care | |
| Cancer 52 | |
| Counsel and Care | |
| Equalities National Council | |
| Helen Rollason Heal Cancer Charity | |
| Leukaemia CARE | |
| Leukaemia Society (UK) | |
| Lymphoma Association | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie Cancer Care | |
| Muslim Council of Britain | |
| Muslim Health Network | |
| Rarer Cancers Foundation | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Sue Ryder Care | |
| Tenovus | |
| Professional groups | Association of Cancer Physicians |
| British Association for Services to the Elderly | |
| British Committee for Standards in Haematology | |
| British Geriatrics Society | |
| British Psychosocial Oncology Society | |
| British Society for Haematology | |
| Cancer Networks Pharmacists Forum | |
| Cancer Research UK | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| United Kingdom Clinical Pharmacy Association | |
| United Kingdom Oncology Nursing Society |
Commentators
| Associated guideline groups | National Collaborating Centre for Cancer |
| Associated public health groups | None |
| Comparator manufacturers | Actavis UK (epirubicin, fludarabine, gemcitabine, prednisolone) |
| Alliance Pharmaceuticals (prednisolone) | |
| Amdipharm (prednisolone) | |
| Auden McKenzie (Pharma Division) (dexamethasone) | |
| Baxter (cyclophosphamide, ifosfamide) | |
| Bristol-Myers Squibb (carboplatin, cisplatin, etoposide) | |
| Chemidex pharma (dexamethasone) | |
| Eli Lilly and Company (gemcitabine) | |
| Genzyme Therapeutics (fludarabine) | |
| Goldshield Critical Care (cisplatin) | |
| Hameln Pharmaceuticals (epirubicin) | |
| Hospira UK (carboplatin, cisplatin, cytarabine, epirubicin, etoposide, fludarabine, gemcitabine) | |
| Medac UK (epirubicin, etoposide, gemcitabine, lomustine) | |
| Merck Sharp & Dohme (dexamethasone) | |
| Mylan (epirubicin, gemcitabine) | |
| Pfizer (cisplatin, cyclophosphamide, cytarabine, epirubicin, methylprednisolone) | |
| Rosemont Pharmaceuticals (dexamethasone) | |
| Sandoz (carboplatin, cisplatin, epirubicin, fludarabine, gemcitabine) | |
| Sigma Pharmaceuticals (methylprednisolone) | |
| Sun Pharmaceuticals UK (carboplatin, gemcitabine) | |
| Teva UK (carboplatin, cisplatin, epirubicin, etoposide, fludarabine, gemcitabine) | |
| Wockhardt UK (carboplatin, cisplatin, epirubicin, fludarabine, gemcitabine) | |
| Evidence Review Group | British Medical Journal (BMJ) |
| National Institute for Health Research Health Technology Assessment Programme | |
| General | Board of Community Health Councils in Wales |
| British National Formulary | |
| Commissioning Support Appraisals Service | |
| Department of Health,Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| NHS Alliance | |
| NHS Commercial Medicines Unit | |
| NHS Confederation | |
| Public Health Wales NHS Trust | |
| Scottish Medicines Consortium | |
| Relevant research groups | British National Lymphoma Investigation |
| Elimination of Leukaemia Fund | |
| Institute of Cancer Research | |
| Leukaemia Busters | |
| Leukaemia & Lymphoma Research | |
| MRC Clinical Trials Unit | |
| National Cancer Research Institute | |
| National Cancer Research Network | |
| National Institute for Health Research | |
| Policy Research Institute on Ageing and Ethnicity | |
| Research Institute of the Care of Older People |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 February 2012 | Following an update on the regulatory status of the technology which has received a negative CHMP opinion, the 25 April 2012 committee meeting discussion for this appraisal has been cancelled. We are monitoring this situation and will provide an update as soon as possible. |
| 1 December 2011 | We have received the latest regulatory timings for pralatrexate from the manufacturer, Allos Therapeutics, and are now able to update our timelines for the above appraisal. The first committee meeting will be held on 25 April 2012. |
| 13 July 2011 |
Following an update from the manufacturer, Allos Therapeutics, on the regulatory timings for pralatrexate the 27 September 2011 committee meeting discussion for the above appraisal has been cancelled. We will update this page with the new timings as soon as possible. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance